SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the ...

SALZBURG, Austria--(BUSINESS WIRE)--Launched as the D-mine ® Pump, this portable micro infusion device recently received European CE approval and is currently being launched in several European ...

An international, multisite phase 3 trial co-led by a University of Cincinnati researcher found Parkinson’s disease medication delivered through an infusion pump is safe and effective at reducing ...

ITCA650 is a unique formulation of exenatide currently in development, which delivers medication through an implantable subcutaneous pump delivery system. The osmotic mini pump provides a slow and ...

AbbVie’s bid to cannibalize its own Parkinson’s disease business has advanced, with the phase 3 success of subcutaneous, pump-delivered levodopa-carbidopa formulation ABBV-951 providing the backbone ...

Remunity Pump is intended for continuous subcutaneous delivery of Remodulin in prefilled cassettes for the treatment of PAH in adults aged ≥22 years. Remunity ® Pump for Remodulin ® (treprostinil; ...

In what’s expected to be one of AbbVie’s “biggest new product launches” in the coming years, the company has hit a snag with its regulatory efforts. The FDA has rejected AbbVie’s application for ...

Ascites is a common complication of cirrhosis of the liver. Build-up of fluid causes the abdomen to swell and may lead to discomfort, difficulty breathing, fatigue, nausea and poor appetite. Treatment ...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Feb. 10, 2021 /PRNewswire/ -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it has launched commercial sales of the ...

Current evidence on the safety of subcutaneous automated low-flow pump implantation for refractory ascites shows there are serious but well-recognised safety concerns, including device failure and ...